Skip to content

Author

K. Vučićević

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access 2026

From data to clinical decision: Optimization of monoclonal antibody dosing in inflammatory bowel diseases

Monoclonal antibodies (mAbs) are key therapies for moderate-to-severe inflammatory bowel disease (IBD). However, substantial interand intraindividual pharmacokinetic variability often leads to suboptimal treatment outcomes. Reactive therapeutic drug monitoring (TDM) is currently recommended, particularly for anti-TNF t...

K. Vučićević · 0 citations
Open access Sep 2026

Connecting the Dots Between Pharmacokinetics, Inflammatory Biomarkers, and Mucosal Healing in Patients on Infliximab with Inflammatory Bowel Disease

Background/Objectives: Mucosal healing (MH) is a key therapeutic target in inflammatory bowel disease (IBD) associated with sustained remission, reduced hospitalisation, and improved outcomes. Its assessment relies on endoscopic evaluation, which is invasive, costly, and not always feasible. Therapeutic drug monitoring...

A. Homšek Ilić, M. Jovanović, S. Marković et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.